z-logo
Premium
Synthesis of Some 1,4,6‐Trisubstituted‐2‐oxo‐1,2‐dihydropyridine‐3‐carbonitriles and Their Biological Evaluation as Cytotoxic and Antimicrobial Agents
Author(s) -
Faidallah Hassan M.,
Rostom Sherif A. F.,
Badr Mona H.,
Ismail Azza E.,
Almohammadi Ameen M.
Publication year - 2015
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201500175
Subject(s) - antimicrobial , cytotoxic t cell , chemistry , candida albicans , cytotoxicity , clotrimazole , staphylococcus aureus , dihydropyridine , biological activity , escherichia coli , combinatorial chemistry , stereochemistry , antifungal , biochemistry , microbiology and biotechnology , bacteria , biology , in vitro , organic chemistry , calcium , genetics , gene
A series of novel 1,4,6‐trisubstituted‐2‐oxo‐1,2‐dihydropyridine‐3‐carbonitriles supported with some functionalities reported to contribute to significant chemotherapeutic potential were synthesized and evaluated for their antimicrobial and/or cytotoxic activities. Thirteen compounds exhibited cytotoxic potential against a panel of three human tumor cell lines. Compounds 15 , 23 , and 24 proved to be the most active agents with a broad spectrum of cytotoxic activity. Analog 24 was considered as the most active cytotoxic agent, being 2.5 times more active than doxorubicin against the colon HT29 carcinoma cell line. Seventeen compounds were able to exert a variable antimicrobial profile, among which analogs 15 , 20 , 21 , 23 , and 24 were prominently active. The highest antimicrobial potential was displayed by analog 24 , being equipotent to ampicillin against Staphylococcus aureus and Escherichia coli , together with a considerable antifungal activity comparable with clotrimazole. Collectively, compounds 15 , 23 , and 24 could be considered as possible dual antimicrobial‐anticancer candidates.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here